Melanoma Clinical Trials

Showing 1001-1020 of 1,477 trials

Real World Study of Four PD-1 Agents in China

NCT03966456

Consecutive patients treated with PD-1 therapy in Qingdao City were included in our study. The effecy and safety of the four PD-1 agents according to clinical outcomes in real world will be studied.

Thoracic CancerGynecologic CancerAbdomen Tumors+1 more

The Affiliated Hospital of Qingdao University500 participantsStarted Jun 2018

Qingdao, Shandong, China

UNKNOWN

The Role of Inflammation in Ocular Tumours

NCT02909517

This prospective, non-therapeutic study will determine whether a novel imaging technique can identify presumptive tumour associated macrophages (TAMs) in patients with ocular tumours. The investigators will evaluate 5 groups: 1. Choroidal nevus 2. Choroidal indeterminate melanocytic lesion 3. Choroidal melanoma 4. Suspected metastatic tumour (ie, primary tumour elsewhere) 5. Locally treated ocular tumours

Ocular Melanoma

Unity Health Toronto30 participantsStarted Mar 2016

Toronto, Ontario, Canada • Toronto, Ontario, Canada

COMPLETEDPhase 1

Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor

NCT01603212

The goal of the Phase I part of this clinical research study is to find the highest tolerable dose of vemurafenib and Aldesleukin (interleukin-2) that can be given in combination with interferon alfa-2b in patients with advanced or metastatic melanoma. The safety of this combination will also be studied. The goal of Phase II is to learn if this study drug combination can help to control advanced or metastatic melanoma.

Melanoma

M.D. Anderson Cancer Center6 participantsStarted Jul 2013

Houston, Texas, United States

Real World Study of Four PD-1 Agents in China

The Role of Inflammation in Ocular Tumours

Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor

Related Searches

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Phase I Study of BCD-145 (Anti-CTLA-4) in Patients With Unresectable/Metastatic Melanoma

Tolerance of Targeted Therapy Used in Metastatic Melanoma in Patients Aged Over 65 and 75-year-old

A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies

Pilot Study of Intervention to Reduce Sunburns in Melanoma Survivors

Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma

Multimodal Spectroscopy (MMS) for in Vivo Noninvasive Assessment of Skin

Adjuvant PEG Intron in Ulcerated Melanoma

Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases

Isolated Limb Perfusion of Melphalan for Melanoma and Sarcoma Treatment

Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma

Employment and Quality of Life in Patients With Malignant Melanoma

Potential Research Study Participant Registry

A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma

Combination Therapy With GEN0101 and Pembrolizmub in Advanced Melanoma Patients PIb/PII

Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma